Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Lotfi Benboubker; Meletios A. Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R. Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je Jung Lee; Christine Chen; Albert Oriol; Javier De La Rubia; Lugui Qiu; Darrell J. White; Daniel Binder; Kenneth Anderson; Jean Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon

doi:10.1056/NEJMoa1402551

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Lotfi Benboubker, Meletios A. Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R. Belch, Michele Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie Cavenagh, Catarina Geraldes, Je Jung Lee, Christine Chen, Albert Oriol, Javier De La Rubia, Lugui QiuDarrell J. White, Daniel Binder, Kenneth Anderson, Jean Paul Fermand, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin-Haynes, Hervé Avet-Loiseau, Cyrille Hulin, Thierry Facon

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article

Abstract

Background: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. Methods: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. Results: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P

Original language	English
Pages (from-to)	906-917
Number of pages	12
Journal	New England Journal of Medicine
Volume	371
Issue number	10
DOIs	https://doi.org/10.1056/NEJMoa1402551
Publication status	Published - Sep 4 2014

Fingerprint

ASJC Scopus subject areas

Medicine(all)

Cite this

Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J. J., Chen, C., Oriol, A., De La Rubia, J., ... Facon, T. (2014). Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. New England Journal of Medicine, 371(10), 906-917. https://doi.org/10.1056/NEJMoa1402551

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. / Benboubker, Lotfi; Dimopoulos, Meletios A.; Dispenzieri, Angela; Catalano, John; Belch, Andrew R.; Cavo, Michele; Pinto, Antonello; Weisel, Katja; Ludwig, Heinz; Bahlis, Nizar; Banos, Anne; Tiab, Mourad; Delforge, Michel; Cavenagh, Jamie; Geraldes, Catarina; Lee, Je Jung; Chen, Christine; Oriol, Albert; De La Rubia, Javier; Qiu, Lugui; White, Darrell J.; Binder, Daniel; Anderson, Kenneth; Fermand, Jean Paul; Moreau, Philippe; Attal, Michel; Knight, Robert; Chen, Guang; Van Oostendorp, Jason; Jacques, Christian; Ervin-Haynes, Annette; Avet-Loiseau, Hervé; Hulin, Cyrille; Facon, Thierry.

In: New England Journal of Medicine, Vol. 371, No. 10, 04.09.2014, p. 906-917.

Research output: Contribution to journal › Article

Benboubker, L, Dimopoulos, MA, Dispenzieri, A, Catalano, J, Belch, AR, Cavo, M, Pinto, A, Weisel, K, Ludwig, H, Bahlis, N, Banos, A, Tiab, M, Delforge, M, Cavenagh, J, Geraldes, C, Lee, JJ, Chen, C, Oriol, A, De La Rubia, J, Qiu, L, White, DJ, Binder, D, Anderson, K, Fermand, JP, Moreau, P, Attal, M, Knight, R, Chen, G, Van Oostendorp, J, Jacques, C, Ervin-Haynes, A, Avet-Loiseau, H, Hulin, C & Facon, T 2014, 'Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma', New England Journal of Medicine, vol. 371, no. 10, pp. 906-917. https://doi.org/10.1056/NEJMoa1402551

Benboubker, Lotfi ; Dimopoulos, Meletios A. ; Dispenzieri, Angela ; Catalano, John ; Belch, Andrew R. ; Cavo, Michele ; Pinto, Antonello ; Weisel, Katja ; Ludwig, Heinz ; Bahlis, Nizar ; Banos, Anne ; Tiab, Mourad ; Delforge, Michel ; Cavenagh, Jamie ; Geraldes, Catarina ; Lee, Je Jung ; Chen, Christine ; Oriol, Albert ; De La Rubia, Javier ; Qiu, Lugui ; White, Darrell J. ; Binder, Daniel ; Anderson, Kenneth ; Fermand, Jean Paul ; Moreau, Philippe ; Attal, Michel ; Knight, Robert ; Chen, Guang ; Van Oostendorp, Jason ; Jacques, Christian ; Ervin-Haynes, Annette ; Avet-Loiseau, Hervé ; Hulin, Cyrille ; Facon, Thierry. / Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. In: New England Journal of Medicine. 2014 ; Vol. 371, No. 10. pp. 906-917.

@article{dd5ff215a19c48589249525a456f09c1,

title = "Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma",

abstract = "Background: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. Methods: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. Results: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P",

author = "Lotfi Benboubker and Dimopoulos, {Meletios A.} and Angela Dispenzieri and John Catalano and Belch, {Andrew R.} and Michele Cavo and Antonello Pinto and Katja Weisel and Heinz Ludwig and Nizar Bahlis and Anne Banos and Mourad Tiab and Michel Delforge and Jamie Cavenagh and Catarina Geraldes and Lee, {Je Jung} and Christine Chen and Albert Oriol and {De La Rubia}, Javier and Lugui Qiu and White, {Darrell J.} and Daniel Binder and Kenneth Anderson and Fermand, {Jean Paul} and Philippe Moreau and Michel Attal and Robert Knight and Guang Chen and {Van Oostendorp}, Jason and Christian Jacques and Annette Ervin-Haynes and Herv{\'e} Avet-Loiseau and Cyrille Hulin and Thierry Facon",

year = "2014",

month = sep

day = "4",

doi = "10.1056/NEJMoa1402551",

language = "English",

volume = "371",

pages = "906--917",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "10",

}

TY - JOUR

T1 - Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

AU - Benboubker, Lotfi

AU - Dimopoulos, Meletios A.

AU - Dispenzieri, Angela

AU - Catalano, John

AU - Belch, Andrew R.

AU - Cavo, Michele

AU - Pinto, Antonello

AU - Weisel, Katja

AU - Ludwig, Heinz

AU - Bahlis, Nizar

AU - Banos, Anne

AU - Tiab, Mourad

AU - Delforge, Michel

AU - Cavenagh, Jamie

AU - Geraldes, Catarina

AU - Lee, Je Jung

AU - Chen, Christine

AU - Oriol, Albert

AU - De La Rubia, Javier

AU - Qiu, Lugui

AU - White, Darrell J.

AU - Binder, Daniel

AU - Anderson, Kenneth

AU - Fermand, Jean Paul

AU - Moreau, Philippe

AU - Attal, Michel

AU - Knight, Robert

AU - Chen, Guang

AU - Van Oostendorp, Jason

AU - Jacques, Christian

AU - Ervin-Haynes, Annette

AU - Avet-Loiseau, Hervé

AU - Hulin, Cyrille

AU - Facon, Thierry

PY - 2014/9/4

Y1 - 2014/9/4

N2 - Background: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. Methods: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. Results: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P

AB - Background: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. Methods: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. Results: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P

UR - http://www.scopus.com/inward/record.url?scp=84907012637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907012637&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1402551

DO - 10.1056/NEJMoa1402551

M3 - Article

C2 - 25184863

AN - SCOPUS:84907012637

VL - 371

SP - 906

EP - 917

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 10

ER -

Access to Document

10.1056/NEJMoa1402551